BeOne Medicines Ltd. American Depositary Shares (ONC)

BeOne Medicines reported positive Phase 1/2 trial results for sonrotoclax in treating mantle cell lymphoma, showing strong response rates and a well-tolerated safety profile. The company plans to submit data to FDA and other regulatory bodies for potential drug approval.

Zymeworks, a clinical-stage biotechnology company, will participate in multiple investor conferences in September 2025, including events hosted by Citi, Wells Fargo, Cantor, and Morgan Stanley, to discuss its biotherapeutics pipeline and recent developments.

Summit Therapeutics' lung cancer drug ivonescimab showed statistically significant improvement in progression-free survival in a phase III trial, outperforming the current standard of care. This positive trial result has sent the company's stock price soaring.